As chair and CEO of Kaiser Permanente, Greg Adams oversaw plenty of change in the last year. In the spring, Kaiser announced plans to acquire Geisinger — what STAT’s Bob Herman called “the biggest proposed health care acquisition in recent memory” — with the goal of creating a national nonprofit health system, Risant Health, which will in turn make five to six additional health system acquisitions over the next few years. (The deal is now under regulatory review.) The fall, meanwhile, brought another momentous event: the resolution of contract negotiations between Kaiser and a coalition of its union members, following a three-day walkout of more than 75,000 workers, the largest health care strike in U.S. history.
More in Business
Business
Behzad Aghazadeh
Managing partner and portfolio manager, Avoro Capital
Business
Kristina Burow
Managing director, ARCH Venture Partners
Business
Susan Galbraith
Executive vice president of oncology research and development, AstraZeneca
Business
Matt Gline
CEO, Roivant Sciences
Business
Reshma Kewalramani
CEO and president, Vertex Pharmaceuticals
Business
Lotte Knudsen
Chief scientific adviser, Novo Nordisk
Business
Peter Lee
Corporate vice president, Microsoft Research & Incubations
Business
Ted Love
Chair, BIO
Business
Karen S. Lynch
CVS Health president and CEO
Business
Joshua Miele
Principal accessibility researcher, Amazon
Business
Umer Raffat
Senior managing director, Evercore ISI
Business
Daniel Skovronsky
Chief scientific officer, Eli Lilly and Company
Business
Tim Van Hauwermeiren
CEO, Argenx
Business
Chris Viehbacher
President and chief executive officer, Biogen
Business
Andrew Witty
CEO, UnitedHealth Group
Fifty influential people shaping the future of health and life sciences across biotech, medicine, health care, policy, and health tech
View the List